Supercharged immune cells take on brain tumor in first human test
NCT ID NCT07172178
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new treatment for malignant meningioma, a rare and aggressive brain tumor. Researchers take a patient's own gamma-delta T cells, arm them with an anti-PD-1 antibody, and inject them directly into the brain tumor cavity. The study will enroll 12 patients to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-PD-1 antibody armored γδ T cells
- What this could lead to
- If successful, this could point toward a new treatment option for malignant meningioma that uses the body's own immune cells to fight the tumor.
- What could go wrong
- This is a very early, small trial (12 people) focused on safety, not yet proven to work. The treatment is injected directly into the brain, which carries risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.